Infutraze

Zinc chloride, potassium iodide, sodium selenite, copper chloride dihydrate, manganese chloride tetrahydrate, the active ingredients in Infutraze, are trace element supplements presented as an intravenous solution for IV use. It provides essential trace elements required for enzymatic activity and metabolic processes in patients receiving parenteral nutrition.

GNH USA supplies Infutraze as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Infutraze is used to address trace element deficiencies in patients receiving parenteral nutrition.

- Prevention of trace element deficiency: maintains adequate zinc, copper, selenium, manganese and iodine levels during total parenteral nutrition. - Treatment of established deficiency: restores deficient trace element concentrations to normal ranges. - Support for malabsorption conditions: supplies essential minerals when gastrointestinal absorption is impaired.

Infutraze may be associated with several adverse reactions when administered intravenously.

Common Side Effects: - Infusion site irritation or phlebitis. - Mild nausea or vomiting. - Transient headache. - Metallic taste. - Mild transient increase in serum copper or zinc levels.

Serious or Rare Side Effects: - Anaphylactic or severe hypersensitivity reactions. - Copper or zinc toxicity manifesting as hepatic dysfunction. - Selenium overdose leading to respiratory distress. - Severe electrolyte imbalance requiring medical intervention. - Acute renal impairment in susceptible patients.

When using Infutraze, clinicians should observe several safety measures.

- Renal function: monitor serum creatinine and adjust dosing in renal impairment. - Hepatic function: assess liver enzymes due to potential copper accumulation. - Pregnancy and lactation: use only if the expected benefit outweighs potential risk. - Allergy assessment: verify no known hypersensitivity to any component. - Compatibility: confirm compatibility with other IV solutions before co‑administration. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Infutraze can interact with other agents that affect trace element balance.

Major Interactions (Avoid): - Concurrent high‑dose copper supplements: risk of copper overload. - High‑dose zinc preparations: may antagonize copper absorption. - Chelating agents (e.g., EDTA): can bind and reduce the availability of administered trace elements.

Moderate Interactions (Monitor Closely): - Thyroid hormone therapy: excess iodine may alter hormone synthesis. - Antioxidant vitamins (vitamin C, E): may influence selenium status. - Renal dialysis: may remove administered trace elements, requiring dose adjustment.